Kristin L Andrejko, Ryan Gierke, Jemma V Rowlands, Jennifer B Rosen, Ann Thomas, Zachary Q Landis, Maria Rosales, Sue Petit, William Schaffner, Corinne Holtzman, Meghan Barnes, Monica M Farley, Lee H Harrison, Lesley McGee, Sopio Chochua, Jennifer R Verani, Adam L Cohen, Tamara Pilishvili, Miwako Kobayashi
BACKGROUND: A U.S. case-control study (2010-2014) demonstrated vaccine effectiveness (VE) for ≥ 1 dose of the thirteen-valent pneumococcal conjugate vaccine (PCV13) against vaccine-type (VT) invasive pneumococcal disease (IPD) at 86 %; however, it lacked statistical power to examine VE by number of doses and against individual serotypes. METHODS: We used the indirect cohort method to estimate PCV13 VE against VT-IPD among children aged < 5 years in the United States from May 1, 2010 through December 31, 2019 using cases from CDC's Active Bacterial Core surveillance, including cases enrolled in a matched case-control study (2010-2014)...
May 3, 2024: Vaccine